Skip to main content
Springer Nature - PMC COVID-19 Collection logoLink to Springer Nature - PMC COVID-19 Collection
. 2008;6(5):394–401. doi: 10.1038/nrmicro1853

Searching for the cause of Kawasaki disease — cytoplasmic inclusion bodies provide new insight

Anne H Rowley 1,, Susan C Baker 2, Jan M Orenstein 3, Stanford T Shulman 1
PMCID: PMC7097362  PMID: 18364728

Although Kawasaki disease (KD) is the most common cause of acquired heart disease in children in the developed world, its aetiology remains unknown. In this Opinion, Anne Rowley and colleagues discuss evidence, including recently identified cytoplasmic inclusion bodies, which suggests that KD is caused by an infectious agent.

Abstract

Kawasaki disease (KD) has emerged as the most common cause of acquired heart disease in children in the developed world. The cause of KD remains unknown, although an as-yet unidentified infectious agent might be responsible. By determining the causative agent, we can improve diagnosis, therapy and prevention of KD. Recently, identification of an antigen-driven IgA response that was directed at cytoplasmic inclusion bodies in KD tissues has provided new insights that could unlock the mysteries of KD.

Main

Kawasaki disease (KD) is an acute childhood illness that usually affects previously healthy infants and children. The disease is manifested by a high spiking fever and, in classic cases, four of five additional features: rash; red eyes; red lips and mouth; swollen and red hands and feet; and swollen glands in the neck. These symptoms resolve spontaneously within 1–3 weeks, or sooner after treatment with intravenous gammaglobulin and aspirin. However, inflammation of medium-sized arteries throughout the body, particularly of the coronary arteries, can occur during the acute illness and result in coronary-artery aneurysms in 25–30% of untreated patients1,2,3,4. In severe cases, KD leads to heart attacks, coronary-artery-aneurysm rupture and/or sudden death5,6. Affected children can require interventions, such as angioplasty or stent placement, coronary-artery-bypass surgery or, rarely, heart transplantation7,8,9,10. Because the features of KD resemble those of other febrile childhood illnesses and as there is no specific diagnostic test for KD, diagnosis can be delayed or never established, which results in a higher likelihood that coronary-artery abnormalities will develop11. Incomplete clinical presentations of KD, in which children present with fever but fewer than four of the other classic features, make diagnosis especially difficult12. Although treatment with intravenous gammaglobulin and aspirin is an effective therapy for KD, its mechanism of action is unknown, not all children respond and the optimal treatment for children with refractory KD remains unclear2,13,14. Identification of the aetiology of KD would greatly enhance efforts to develop a diagnostic test, improve therapy and prevent KD.

Clinical features of KD that support an infectious cause include: abrupt onset of symptoms that are compatible with infection, and resolution of the illness in 1–3 weeks, even without treatment and usually without recurrence. The young age group that is affected, the winter–spring predominance of cases in non-tropical climates and the existence of epidemics or clusters of cases that spread in a wave-like manner throughout a community also suggest an infectious cause15. In the 40 years since Tomisaku Kawasaki initially described the clinical features of KD16, many possible aetiological agents have been suggested (Table 1), but none have been confirmed by subsequent study. Studies of KD aetiology and pathogenesis are fraught with difficulties. Accessing the most important target tissue of the disease, the coronary artery, for aetiological and pathogenic studies is not possible in living patients. As KD is an illness of small children, there are also ethical constraints on obtaining biopsy samples for research studies from lymph nodes and other tissues. So far, it has not been possible to reproduce the disease in an animal model by injecting blood, body fluids or tissue samples from acutely ill patients.

Table 1.

Aetiological agents postulated for Kawasaki disease

Postulated agent Proposed pathogenesis Current status Refs
Mercury Direct toxic effect Lack of supporting evidence 98
Rickettsia-like agent Infection of macrophages and/endothelial cells Lack of supporting evidence 36
Propriobacterium acnes Infection of macrophages and/endothelial cells Lack of supporting evidence 35
Rug shampoo Aerosolization of mites or a direct toxic effect Lack of supporting evidence 37–39
Leptospira spp. Infection of endothelial cells Lack of supporting evidence 99
Streptococcus sanguis Infection or toxin effect Lack of supporting evidence 100
Retrovirus Infection of lymphocytes Lack of supporting evidence 40–43
Epstein–Barr virus or cytomegalovirus Infection of various cell types Lack of supporting evidence 101,102
Toxic shock syndrome toxin 1 (TSST1) Superantigen-induced immune response Not confirmed by follow-up studies 44–46
Bacterial toxin other than TSST1 Superantigen-induced immune response Lack of supporting evidence; still under investigation 72–74
Coronavirus NL-63 None Not confirmed by follow-up studies 47–49
Human bocavirus None Reported by one group; currently unconfirmed 50
Previously unrecognized persistent RNA virus Infection of targeted cells with antigen-driven immune response; cytoplasmic inclusion bodies are formed and can persist Under investigation 17–22, 87

By examining tissue samples from fatal cases of KD, recent progress has been made in understanding KD aetiology and pathogenesis17,18,19,20,21,22. These studies revealed that oligoclonal IgA plasma cells infiltrate inflamed tissues, including coronary arteries17,18. Synthetic versions of these oligoclonal KD antibodies bind to an antigen in acute-KD-inflamed ciliated bronchial epithelium21. Light and electron microscopy studies have demonstrated that the antigen is localized to cytoplasmic inclusion bodies in tissues inflamed by acute KD22. In this Opinion, we discuss pathological and immunological findings of acute KD, with an emphasis on the IgA immune response and its antigenic targets, and on the importance of macrophages and their secreted factors in the pathogenesis of coronary-artery-aneurysm formation. Although other theories of KD aetiology will be discussed, our primary goal is to highlight a new pathway of discovery in KD research: the identification of IgA plasma cells in tissues inflamed by KD and the subsequent identification of viral-like cytoplasmic inclusion bodies in tissues inflamed by KD. The proposed pathogenesis of KD described below and illustrated in Fig. 1 represents the opinion of the authors, which was formed on the basis of these findings and the well-described pathological features of KD.

Figure 1. Proposed pathogenesis of Kawasaki disease.

Figure 1

a | The Kawasaki disease (KD) agent is inhaled, and infects medium-sized ciliated bronchial epithelial cells. Tissue macrophages engulf the agent and initiate innate immune responses. Antigens are then carried to local lymph nodes, where they initiate adaptive immune responses. b | Bronchial epithelial cells are infiltrated by macrophages and by antigen-specific T lymphocytes and IgA plasma cells; some epithelial cells are denuded. c | Monocytes and/or macrophages that contain the KD agent enter the bloodstream and traffic through organs and tissues, which allows the agent to infect specific susceptible tissues, especially vascular and ductal tissues. An immune response and/or treatment with intravenous immunoglobulin can successfully contain the KD agent, possibly by an antibody-dependent cellular cytotoxicity mechanism (not shown). d | In the bronchial epithelium, the KD agent shuts down the production of viral proteins and retreats into cytoplasmic inclusion bodies that are not recognized by the immune system and therefore persist. e | The KD agent occasionally reactivates, and can infect nearby bronchial epithelial cells and enter the environment through coughing or sneezing. The secondary immune response is then stimulated and the agent retreats back into inclusion bodies.

History of KD aetiology studies

Clinical, epidemiological and pathological studies of KD that were performed in Japan in the 1970s and 1980s quickly led to the hypothesis that an infectious agent is the cause of KD. A ubiquitous agent is suspected because of the rarity of KD in infants under 2 months of age (young infants could be protected by passive maternal antibodies) and in adults (who could have experienced asymptomatic infection during childhood), and because most cases present during the first or second year of life (when susceptibility to most ubiquitous agents is highest)15,23,24. KD affects all ethnic and racial groups worldwide, but the markedly higher attack rate of KD in children of Asian ethnicity suggests a genetic predisposition to symptomatic infection; an increased attack rate is also observed in Japanese–American children who have a Western diet and lifestyle25. By the age of 5, 1 in 150 Japanese children26, 1 in 1,000 Black children from the United States27 and 1 in 2,000 Caucasian children from the United States27 will have developed KD. Siblings of patients with KD and children whose parents have a history of KD are at higher risk than the general population28,29. Genetic susceptibility to KD is probably polygenic — polymorphisms in several genes that are related to an immune response, such as interleukin-4, chemokine receptor 5, chemokine (C-C motif) ligand 3-like 1 and inositol phosphate kinase C30,31,32, have been implicated, which is compatible with an aetiology that is probably infectious. Genome-wide linkage analysis has revealed linkage of KD with chromosome 12q24, and multiple candidate genes are located in this chromosomal region33.

Extensive culture and serological studies have not been successful25,34, and none of the proposed agents have been confirmed35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50 (Table 1). It has been suggested that KD is caused by multiple aetiological agents, because various microorganisms have been isolated from individual patients with KD51,52. Although several illnesses that are not associated with fever and primarily involve a one-organ system can be triggered by diverse infectious agents, such as Reye syndrome and haemolytic uraemic syndrome, there is no precedent for a multisystem febrile childhood illness with distinctive clinical features, such as KD, to be the result of multiple diverse aetiological agents. Some childhood febrile illnesses, such as polio, roseola and fifth disease, were suggested to be the result of multiple agents, but were later found to be due to a single infectious agent or a group of closely related infectious agents. Because KD is a common illness, it is more likely that KD occasionally coexists with other infections, without causal relationships.

The hypothesis that a bacterial toxin causes KD is still favoured by some investigators. This theory is based on clinical similarities between KD and staphylococcal or streptococcal toxin-mediated illnesses, such as the peeling of hands and feet and strawberry tongue, on the finding that many cytokines are upregulated in the serum of patients with acute KD53,54,55,56,57 and on reports of over-representation of particular T-lymphocyte-receptor Vβ families in the peripheral blood of some patients with acute KD.

Expansions of T lymphocytes that possess Vβ2 and Vβ8 (Refs 58–60), Vβ2 and Vβ6 (Ref. 61) or Vβ2 and Vβ5 (Ref. 62) during acute KD have been reported by some investigators, whereas others have not observed Vβ expansion during acute KD63,64,65. Predominant Vβ-T-lymphocyte-receptor usage, even if present in patients with acute KD, does not necessarily implicate a superantigen or bacterial-toxin aetiology of KD. Restriction of Vβ-T-lymphocyte-receptor usage can result from conventional antigens, including those expressed by lymphocytic choriomeningitis virus66, influenza virus67, reovirus68, herpes simplex virus69 and hepatitis C virus70. Complementarity-determining region 3 (CDR3) size profiling and sequencing of the CDR3 regions of expanded Vβ-family members is probably the best way to determine whether an expansion is the result of a conventional antigen or a superantigen. In two studies that lacked CDR3 size profiling but included sequencing of PCR products, clonality was not observed in the one Vβ family that was sequenced from eight patients with KD or in the two Vβ families that were sequenced from one patient with KD. In another study in which CD4+ and CD8+ T lymphocytes from eight patients with acute KD were separated and Vβ families from each compartment were amplified by PCR, CDR3 size profiling and sequencing revealed clonal expansions of CD8+ T lymphocytes71. Additional experiments that include separation of the CD4+ and CD8+ compartments and CDR3 size profiling and sequencing of expanded Vβ families might resolve these discrepancies.

Studies that have examined possible antibody responses to various bacterial superantigens in patients with KD are similarly conflicting72,73,74,75. A study that implicated colonization of mucosal surfaces of patients with acute KD with toxic shock syndrome toxin 1-producing strains of Staphylococcus aureus as being aetiologically related to acute KD44 was not confirmed by subsequent study46. To explain the multisystem nature of acute KD, a bacterial toxin would need to circulate in the bloodstream, but no bacterial toxin has been detected as yet in the peripheral blood of patients with KD.

An autoimmune mechanism of KD pathogenesis has also been proposed76. The spontaneous resolution of KD and its generally non-recurring nature make this theory less attractive.

Recently, cytoplasmic inclusion bodies were identified in the ciliated bronchial epithelium of children with fatal acute KD22. The presence of inclusion bodies in inflamed tissues during an acute illness such as KD is highly suggestive of an infection that is due to an intracellular pathogen, such as a virus. These inclusion bodies were identified using synthetic versions of IgA antibodies that are prevalent in the acute KD arterial wall, which provides strong support for their role in KD aetiology and pathogenesis19,20,21,22.

Pathological findings in KD

KD is a systemic inflammatory disease that affects many organs and tissues. Ductal tissues and arterial tissues seem to be particularly targeted by the inflammatory process77 (Fig. 1). From a clinical perspective, the most important aspect of KD pathology is inflammation of the medium-sized arteries, and particularly of the coronary arteries. Although endothelial cells are a major target of the disease process (Figs 1, 2), they are clearly not the only target. Theories of KD aetiology that propose an endothelial cell antigen that is targeted by the immune system as the exclusive mechanism of disease pathogenesis fail to explain the presence of bronchitis, pancreatic and prostatic ductitis and other pathological features that are observed in autopsy studies of patients with KD77, as well as the myocarditis that is noted in endomyocardial biopsies from living patients with KD78 (Box 1). Infiltrating macrophages, T lymphocytes and cellular components of the arterial wall, such as myofibroblasts, are important in disease pathogenesis and might secrete a number of inflammatory mediators, enzymes and other molecules, such as vascular endothelial growth factor (VEGF), which contributes to vascular leakage and oedema79 (Fig. 2).

Figure 2. Proposal of events that lead to coronary-artery aneurysms in acute Kawasaki disease.

Figure 2

a | A small subset of circulating monocytes and/or macrophages contain the Kawasaki disease (KD) agent; these adhere to endothelial cells, and can enter the arterial wall at the intimal surface and through small arteries (vaso vasorum) in the adventitia. b | Infection of an artery leads to infiltration of additional circulating monocytes and/or macrophages. Macrophages secrete vascular endothelial growth factor (VEGF), matrix metalloproteinase 9 (MMP9), tumour necrosis factor-α (TNF-α) and other cytokines and enzymes. Antigens of the KD agent are processed by major histocompatibility complex class I. Antigen-specific CD8+ T lymphocytes target infected cells for destruction. Antigen-specific IgA B cells develop into plasma cells following exposure to local cytokines; specific antibody is produced to combat the agent. The intima is destroyed as endothelial cells become necrotic and are sloughed, and the thrombus adheres to this damaged surface. Subsequently, internal and external elastic laminae are fragmented, collagen fibres are disrupted and smooth muscle cells become necrotic; media and adventitia are no longer distinct. The structural integrity of the artery is then lost, and ballooning occurs. Myofibroblasts that secrete VEGF and MMP2 proliferate and can enter the organized thrombus, thereby forming neointima that can thicken over time. Neoangiogenesis in neointima and adventitia also occurs. c| The adjacent area of the artery that is not infiltrated by monocytes and/or macrophages that contain the KD agent is not affected.

Immunological findings in acute KD

KD is an interesting example of an illness in which the distribution of inflammatory cell types in peripheral blood differs markedly from that in target tissues (Table 2). Therefore, studies that focus solely on peripheral blood could be misleading. Blood levels of many pro-inflammatory cytokines are elevated during acute KD, as might be expected in an illness that is manifested by prolonged fever and multiorgan-system inflammation53,54,55,56,57.

Table 2.

Immunological features of acute Kawasaki disease

Immune response Peripheral blood Arterial wall
Predominant inflammatory cell type Mature and immature neutrophil predominance CD45RO+ T lymphocyte80, macrophage80,91, eosinophil95, IgA plasma cell17,18 and activated myeloid dendritic cell96 predominance
Relative proportion of CD4+ and CD8+ T lymphocytes CD4+ to CD8+ T lymphocyte ratio of >2; ratio of CD4+ to CD8+ T lymphocytes of 3.5 in the second week of illness in patients who develop coronary-artery aneurysms97 CD8+ T lymphocytes predominate over CD4+ T lymphocytes80

Macrophages are particularly numerous in intimal and adventitial layers of coronary-artery aneurysms80. These macrophages are the likely source of matrix metalloproteinases (MMPs), such as MMP2 and MMP9, and other enzymes that can disrupt collagen and elastin fibres and weaken the arterial wall, thereby causing it to lose its structural integrity, after which it expands into an aneurysm81 (Fig. 2). VEGF and its receptor FLT1 are upregulated in endothelium, in vascular media and in macrophages in the arterial wall, and probably contribute to vascular permeability79. E-selectin and vascular cell adhesion molecule 1 are observed on perivascular (adventitial) new blood vessels in the coronary-artery-aneurysm wall, and may promote endothelial cell-inflammatory cell interactions and entry of macrophages and lymphocytes into arterial tissue82. Years after the onset of KD, various growth factors, such as transforming growth factor-β1, platelet-derived growth factor-A (PDGF-A) and basic fibroblast growth factor (bFGF), are expressed in the arterial wall and could contribute to the neoangiogenesis and intimal proliferation that are often observed in autopsy studies of late-stage-KD deaths83. VEGF and bFGF, and to a lesser extent PDGF-A, have been detected in inflammatory cells that infiltrate coronary aneurysms during acute KD, indicating that vascular remodelling and neoangiogenesis are ongoing even during the acute phase84 (Fig. 2).

Inflammatory cells in non-vascular tissues are generally also lymphocytes and large atypical mononuclear cells, macrophages and plasma cells18,77. No purulence is noted in lymph nodes or other tissues, and neutrophils constitute only a small fraction of the inflammatory cells in inflamed KD tissues.

The IgA immune response in acute KD

While screening an acute KD arterial-expression cDNA library with convalescent sera from patients with KD, it became apparent that many immunoglobulin-α clones were present in the library17. Further study showed that IgA plasma-cell infiltration of the arterial wall was characteristic of acute KD17, which prompted examination of non-vascular tissues. IgA plasma cells infiltrate the upper respiratory tract of patients with acute KD, often in a peribronchial distribution18. Examination of other tissues inflamed by KD revealed IgA plasma-cell infiltration in the pancreas (during acute KD), especially around the pancreatic ducts and in the kidneys18. Absolute numbers of IgA B lymphocytes were decreased in peripheral blood in patients with acute KD compared with controls, which suggests that these cells may selectively enter target tissues of the disease in a manner that is similar to CD8+ T lymphocytes85.

To determine whether IgA plasma cells in tissues inflamed by KD were oligoclonal (producing a restricted repertoire of antibodies, a characteristic feature of a specific, antigen-driven response) or polyclonal (producing a broad repertoire of antibodies without restriction of the response), the clonality of IgA genes in arterial tissue inflamed by acute KD was examined. Immunoglobulin heavy-chain α-genes that had been identified in the arterial wall of three children who had died of acute KD were sequenced in the CDR3 (antigen-binding) region, which revealed that each of the three patients had a restricted pattern of CDR3 usage that was characteristic of an antigen-driven response19. In this study, unfixed tissue was available from one of the three patients, and immunoglobulin α-genes from a primary cDNA library that had been made from this patient showed evidence of somatic mutation among the sequences, again supporting an antigen-driven response19.

Generation of synthetic KD antibodies. To determine whether KD oligoclonal IgA antibodies were targeting a specific antigen (or antigens) in tissues inflamed by acute KD, α-heavy-chain immunoglobulin variable-region sequences that were present in arterial tissue inflamed by KD were cloned and a panel of monoclonal antibodies was generated20. Antibodies made from immunoglobulin α-sequences that were more prevalent in the inflamed arterial tissue bound to acute-KD-ciliated bronchial epithelium much more strongly than antibodies that were made from less-prevalent sequences, which is consistent with an antigen-driven response20.

KD antigen in cytoplasmic inclusion bodies. The synthetic KD antibodies detected antigen in ciliated bronchial epithelium from patients with acute KD, but not in ciliated bronchial epithelium from infant controls21. Antigen was also detected in a subset of macrophages in inflamed tissues from patients with acute KD21. In bronchial epithelium, the intracytoplasmic spheroidal antigen that was detected had the morphological appearance of an inclusion body (Fig. 1). Haematoxylin and eosin-stained bronchial epithelium from patients with acute KD revealed corresponding amphophilic bodies, which suggests the presence of both nucleic acid and protein in the bodies22. Transmission electron microscopy confirmed that the spheroidal bodies were homogeneous, granular, intracytoplasmic inclusion bodies (ICIs)22. These studies showed that acute-stage-KD-ciliated bronchial epithelium contained ICIs that are consistent with aggregates of viral proteins and nucleic acids22.

We propose that identification of these proteins and nucleic acids will lead to the identification of the KD aetiological agent. Some examples of viruses that produce granular ICIs in infected tissues are the paramyxoviruses, reoviruses, poxviruses and filoviruses; the ICIs usually represent aggregates of viral proteins or nucleocapsids86. Recent data indicate that ICIs are present in ciliated bronchial epithelium in approximately 85% of the children with KD who die in the first 2 months after the onset of KD and in approximately the same percentage of children who die more than 10 weeks after disease onset (when inflammation has generally subsided). Nucleic acid stains indicate that ICIs contain RNA, but not DNA. Although ICIs were not detected in the ciliated bronchial epithelium of control infants, they were present in the ciliated bronchial epithelium from approximately 25% of the control patients who were 9–84 years old. These older control patients had probably experienced asymptomatic infection with the ubiquitous KD agent; this high prevalence of ICIs in older control patients suggests that the KD agent can cause persistent infection. Taken together, these findings are consistent with a ubiquitous, persistent RNA virus as the aetiological agent of KD87.

We propose a model of KD pathogenesis in which the aetiological agent of KD enters through the respiratory tract and infects ciliated bronchial epithelium, where it forms ICIs (Fig. 1). The agent might enter the bloodstream via macrophages, as a result of either infection or uptake by the cells that act as scavengers, before being carried to its target tissues, particularly coronary arteries, other arterial tissue and ductal tissues. Antigen-specific IgA plasma cells and CD8+ T lymphocytes infiltrate the targeted tissues to combat the pathogen and contain the infection, but the coronary arteries might be damaged by the products of activated macrophages and lymphocytes, such as MMPs. Alternatively, the infection could be controlled through gammaglobulin therapy by the provision of specific antibody, perhaps via antibody-mediated cellular cytotoxicity88,89,90 (the mechanism for the dramatic clinical response of patients with Argentine haemorrhagic fever, an arenavirus infection to immune gammaglobulin).

The future

The limited availability of unfixed tissue samples from patients with KD has impeded our progress in understanding the aetiology and pathogenesis of the disease. Identification of the KD aetiological agent will be accelerated by the placement of biopsy or autopsy tissues from patients with KD into an optimal cutting-temperature compound for storage at −70°C, into liquid nitrogen for rapid freezing with storage at −70°C and into glutaraldehyde and formalin. Ultrastructural analysis of ICIs in glutaraldehyde-fixed tissue and molecular studies of unfixed tissues will facilitate rapid progress. The new finding that ICIs are present in 25% of normal control patients might make more tissue available for research. The goal of these studies is to identify the causative agent of KD so that a diagnostic test and better therapies can be developed. Additional research on the genetics of KD could enable the identification of patients who are at high risk of the disease. The long-term goal of KD aetiology and pathogenesis research is to prevent the disease by vaccination or other strategies.

Box 1 | Pathological features of Kawasaki disease.

Blood vessels

Kawasaki disease affects medium-sized arteries, which experience both intimal and perivascular inflammation, most severely91,92,93.

Stage one. Includes: oedema, proliferation and degeneration of endothelial cells; desquamation and oedema of the subendothelial space; adherence of fibrin and platelets; and mild inflammation in endothelial, subendothelial and perivascular spaces.

Stage two. A moderate number of inflammatory cells infiltrate subendothelial spaces, thereby causing swelling and splitting of the internal elastic lamina. Severe oedema then results in necrosis of the medial smooth-muscle cells, and a moderate number of inflammatory cells infiltrate the adventitia.

Stage three. Necrotizing panarteritis, with inflammatory-cell infiltration into all layers of the vascular wall, is associated with degeneration and necrosis of cells in the vascular wall and splitting or fragmentation of the internal and external elastic laminae.

Stage four. Proliferation of cells with features of both myocytes and fibroblasts in the intima and media, together with mild inflammatory-cell infiltration and an accumulation of fibrinoid material along the luminal surface.

Stage five. Fibrous connective tissue replaces the intima and media; collagen and elastin fibres proliferate in the adventitia; the vascular wall is thickened; and, in severe cases, the lumen becomes stenotic or occluded.

Stage six. Internal and external elastic laminae are stretched and fragmented, and an aneurysm forms. The intima, media and adventitia are no longer distinguishable, and a thrombus may be present in the lumen. Aneurysms most commonly develop in the coronary and iliac arteries.

All six stages can be observed in different arteries in a single patient at the same time, as well as in different regions of one artery. By 2 months after onset, inflammation will have subsided and granulation tissue will have formed. Calcification may occur, along with organization and/or recanalization of the thrombus.

Non-vascular tissues

Heart. Can exhibit endocarditis, myocarditis and/or pericarditis77,91,92,93.

Alimentary tract. Inflammation can be present in the tongue, salivary glands, small intestine, gastrointestinal-associated lymphoid tissue, liver (especially bile ducts) and pancreas (especially pancreatic ducts)77.

Respiratory tract. Can exhibit peribronchial inflammation, necrosis and desquamation of bronchial mucosal epithelium, segmental interstitial pneumonia and, rarely, pleuritis and lung nodules77,94.

Urinary system. Can exhibit periglomerular interstitial inflammation, prostatitis (mainly of the prostatic ducts) and/or cystitis77.

Nervous system. Can exhibit aseptic leptomeningitis, choriomeningitis and/or inflammation around the ganglia77.

Lymphoreticular system. Can exhibit enlarged lymph nodes with reactive hyperplasia and/or a congested spleen77.

Inflammation in the lung, spleen, salivary glands and lymph nodes can be persistent or recurrent77.

Acknowledgements

Research in the laboratory of A.H.R. is supported by National Institutes of Health (grant HL63771) and The Kawasaki Disease Fund of the Children's Memorial Hospital. Research in the laboratory of S.C.B. is supported by the Research Funding Committee of Loyola University Stritch School of Medicine (grant LU109703).

Biographies

Anne Rowley is Professor of Pediatrics and Microbiology/Immunology at Northwestern University Feinberg School of Medicine and an attending physician in the Division of Infectious Diseases at Children's Memorial Hospital, Chicago, Illinois, USA. She received her M.D. from SUNY Upstate Medical School, New York, USA. Her research focuses on the aetiology and pathogenesis of Kawasaki disease.

Susan Baker is a professor in the Department of Microbiology and Immunology at the Stritch School of Medicine, Loyola University of Chicago, Illinois, USA. She received her Ph.D. in microbiology from Vanderbilt University, Tennessee, USA, before carrying out postdoctoral studies at the University of Southern California, USA. Her research focuses on investigating the replication of coronaviruses and pursuing the aetiology of Kawasaki disease.

Jan Orenstein is Professor of Pathology at the George Washington University School of Medicine, Washington DC, USA. For the past 25 years, he has focused his research on the pathology of HIV-1 AIDS, and studies both the virus and the opportunistic infections that accompany the disease. During the past several years he has also studied the pathology and pathogenesis of Kawasaki disease.

Stanford Shulman is the Virginia H. Rogers Professor of Pediatric Infectious Diseases at Northwestern University Feinberg School of Medicine and Chair of the Division of Infectious Diseases at Children's Memorial Hospital, Chicago, Illinois, USA. He received his M.D. from the University of Chicago Medical School. His research interests focus on the group A streptococcus, endocarditis and Kawasaki disease.

Related links

FURTHER INFORMATION

Anne H. Rowley's homepage

References

  • 1.Suzuki A, et al. Coronary arterial lesions of Kawasaki disease: cardiac catheterization findings of 1100 cases. Pediatr. Cardiol. 1986;7:3–9. doi: 10.1007/BF02315475. [DOI] [PubMed] [Google Scholar]
  • 2.Newburger JW, et al. The treatment of Kawasaki syndrome with intravenous gammaglobulin. N. Engl. J. Med. 1986;315:341–347. doi: 10.1056/NEJM198608073150601. [DOI] [PubMed] [Google Scholar]
  • 3.Kato H, et al. Long-term consequences of Kawasaki disease. A 10- to 21-year follow-up study of 594 patients. Circulation. 1996;94:1379–1385. doi: 10.1161/01.CIR.94.6.1379. [DOI] [PubMed] [Google Scholar]
  • 4.Newburger JW, et al. Diagnosis, treatment, and long-term management of Kawasaki disease. Circulation. 2004;110:2747–2771. doi: 10.1161/01.CIR.0000145143.19711.78. [DOI] [PubMed] [Google Scholar]
  • 5.Landing BH, Larson EJ. Pathologic features of Kawasaki disease. Am. J. Cardiovasc. Pathol. 1987;1:218–229. [PubMed] [Google Scholar]
  • 6.Nakano H, Saito A, Ueda K, Nojima K. Clinical characteristics of myocardial infarction following Kawasaki disease: report of 11 cases. J. Pediatr. 1986;108:198–203. doi: 10.1016/S0022-3476(86)80982-9. [DOI] [PubMed] [Google Scholar]
  • 7.Akagi T, et al. Catheter interventional treatment in Kawasaki disease: a report from the Japanese Pediatric Interventional Cardiology Investigation Group. J. Pediatr. 2000;137:181–186. doi: 10.1067/mpd.2000.107164. [DOI] [PubMed] [Google Scholar]
  • 8.Kitamura S, et al. Long-term outcome of myocardial revascularization in patients with Kawasaki coronary artery disease. J. Thorac. Cardiovasc. Surg. 1994;107:663–674. [PubMed] [Google Scholar]
  • 9.Suzuki A, Kamiya T, Ono Y, Okuno M, Yagihara T. Aortocoronary bypass surgery for coronary arterial lesions resulting from Kawasaki disease. J. Pediatr. 1990;116:567–573. doi: 10.1016/S0022-3476(05)81604-X. [DOI] [PubMed] [Google Scholar]
  • 10.Checchia PA, Pahl E, Shaddy RE, Shulman ST. Cardiac transplantation for Kawasaki disease. Pediatrics. 1997;100:695–699. doi: 10.1542/peds.100.4.695. [DOI] [PubMed] [Google Scholar]
  • 11.Anderson MS, Todd JK, Glode MP. Delayed diagnosis of Kawasaki syndrome: an analysis of the problem. Pediatrics. 2005;115:e428. doi: 10.1542/peds.2004-1824. [DOI] [PubMed] [Google Scholar]
  • 12.Rowley AH, Gonzalez-Crussi F, Gidding SS, Duffy CE, Shulman ST. Incomplete Kawasaki disease with coronary artery involvement. J. Pediatr. 1987;110:409–413. doi: 10.1016/S0022-3476(87)80503-6. [DOI] [PubMed] [Google Scholar]
  • 13.Newburger JW, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N. Engl. J. Med. 1991;324:1633–1639. doi: 10.1056/NEJM199106063242305. [DOI] [PubMed] [Google Scholar]
  • 14.Wallace CA, French JW, Kahn SJ, Sherry DD. Initial intravenous gammaglobulin treatment failure in Kawasaki disease. Pediatrics. 2000;105:e78. doi: 10.1542/peds.105.6.e78. [DOI] [PubMed] [Google Scholar]
  • 15.Yanagawa H, Nakamura Y, Kawasaki T, Shigematsu I. Nationwide epidemic of Kawasaki disease in Japan during winter of 1985–86. Lancet. 1986;2:1138–1139. doi: 10.1016/S0140-6736(86)90541-6. [DOI] [PubMed] [Google Scholar]
  • 16.Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children. Arerugi. 1967;16:178–222. [PubMed] [Google Scholar]
  • 17.Rowley AH, Eckerley CA, Jack HM, Shulman ST, Baker SC. IgA plasma cells in vascular tissue of patients with Kawasaki syndrome. J. Immunol. 1997;159:5946–5955. [PubMed] [Google Scholar]
  • 18.Rowley AH, et al. IgA plasma cell infiltration of proximal respiratory tract, pancreas, kidney, and coronary artery in acute Kawasaki disease. J. Infect. Dis. 2000;182:1183–1191. doi: 10.1086/315832. [DOI] [PubMed] [Google Scholar]
  • 19.Rowley AH, Shulman ST, Spike BT, Mask CA, Baker SC. Oligoclonal IgA response in the vascular wall in acute Kawasaki disease. J. Immunol. 2001;166:1334–1343. doi: 10.4049/jimmunol.166.2.1334. [DOI] [PubMed] [Google Scholar]
  • 20.Rowley AH, et al. Cloning the arterial IgA antibody response during acute Kawasaki disease. J. Immunol. 2005;175:8386–8391. doi: 10.4049/jimmunol.175.12.8386. [DOI] [PubMed] [Google Scholar]
  • 21.Rowley AH, et al. Detection of antigen in bronchial epithelium and macrophages in acute Kawasaki disease by use of synthetic antibody. J. Infect. Dis. 2004;190:856–865. doi: 10.1086/422648. [DOI] [PubMed] [Google Scholar]
  • 22.Rowley AH, et al. Cytoplasmic inclusion bodies are detected by synthetic antibody in ciliated bronchial epithelium during acute Kawasaki disease. J. Infect. Dis. 2005;192:1757–1766. doi: 10.1086/497171. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Yanagawa H, Yashiro M, Nakamura Y, Kawasaki T, Kato H. Epidemiologic pictures of Kawasaki disease in Japan: from the nationwide incidence survey in 1991 and 1992. Pediatrics. 1995;95:475–479. [PubMed] [Google Scholar]
  • 24.Yanagawa H, et al. Changes in epidemic patterns of Kawasaki disease in Japan. Pediatr. Infect. Dis. J. 1989;18:64–66. doi: 10.1097/00006454-199901000-00015. [DOI] [PubMed] [Google Scholar]
  • 25.Dean AG, Melish ME, Hicks R, Palumbo NE. An epidemic of Kawasaki syndrome in Hawaii. J. Pediatr. 1982;100:552–557. doi: 10.1016/S0022-3476(82)80751-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yanagawa H, et al. Incidence of Kawasaki disease in Japan: the nationwide surveys of 1999–2002. Pediatr. Int. 2006;48:356–361. doi: 10.1111/j.1442-200X.2006.02221.x. [DOI] [PubMed] [Google Scholar]
  • 27.Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics. 2003;112:495–501. doi: 10.1542/peds.112.3.495. [DOI] [PubMed] [Google Scholar]
  • 28.Fujita Y, et al. Kawasaki disease in families. Pediatrics. 1989;84:666–669. [PubMed] [Google Scholar]
  • 29.Uehara R, Yashiro M, Nakamura Y, Yanagawa H. Kawasaki disease in parents and children. Acta Paediatr. 2003;92:694–697. doi: 10.1111/j.1651-2227.2003.tb00602.x. [DOI] [PubMed] [Google Scholar]
  • 30.Burns JC, et al. Family-based association analysis implicates IL-4 in susceptibility to Kawasaki disease. Genes Immun. 2005;6:438–444. doi: 10.1038/sj.gene.6364225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Burns JC, et al. Genetic variations in the receptor–ligand pair CCR5–CCL3L1 are important determinants of susceptibility to Kawasaki disease. J. Infect. Dis. 2005;192:344–349. doi: 10.1086/430953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Onouchi Y, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nature Genet. 2007;40:35–42. doi: 10.1038/ng.2007.59. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Onouchi Y, et al. A genomewide linkage analysis of Kawasaki disease: evidence for linkage to chromosome 12. J. Hum. Genet. 2007;52:179–190. doi: 10.1007/s10038-006-0092-3. [DOI] [PubMed] [Google Scholar]
  • 34.Bell DM, et al. Kawasaki syndrome: description of two outbreaks in the United States. N. Engl. J. Med. 1981;304:1568–1575. doi: 10.1056/NEJM198106253042603. [DOI] [PubMed] [Google Scholar]
  • 35.Kato H, et al. Variant strain of Propionibacterium acnes: a clue to the aetiology of Kawasaki disease. Lancet. 1983;2:1383–1387. doi: 10.1016/S0140-6736(83)90921-2. [DOI] [PubMed] [Google Scholar]
  • 36.Hamashima Y, Kishi K, Tasaka K. Rickettsia-like bodies in infantile acute febrile mucocutaneous lymph node syndrome. Lancet. 1973;2:42. doi: 10.1016/S0140-6736(73)91975-2. [DOI] [PubMed] [Google Scholar]
  • 37.Patriarca PA, et al. Kawasaki syndrome: association with the application of rug shampoo. Lancet. 1982;2:578–580. doi: 10.1016/S0140-6736(82)90660-2. [DOI] [PubMed] [Google Scholar]
  • 38.Lin FY, Bailowitz A, Koslowe P, Israel E, Kaslow RA. Kawasaki syndrome: a case-control study during an outbreak in Maryland. Am. J. Dis. Child. 1985;139:277–279. doi: 10.1001/archpedi.1985.02140050071025. [DOI] [PubMed] [Google Scholar]
  • 39.Klein BS, et al. Kawasaki syndrome: a controlled study of an outbreak in Wisconsin. Am. J. Epidemiol. 1986;124:306–316. doi: 10.1093/oxfordjournals.aje.a114389. [DOI] [PubMed] [Google Scholar]
  • 40.Shulman ST, Rowley AH. Does Kawasaki disease have a retroviral etiology? Lancet. 1986;2:545–546. doi: 10.1016/S0140-6736(86)90115-7. [DOI] [PubMed] [Google Scholar]
  • 41.Burns JC, et al. Polymerase activity in lymphocyte culture supernatants from patients with Kawasaki disease. Nature. 1986;323:814–816. doi: 10.1038/323814a0. [DOI] [PubMed] [Google Scholar]
  • 42.Melish ME, et al. Absence of significant RNA-dependent DNA polymerase activity in lymphocytes from patients with Kawasaki syndrome. Nature. 1989;337:288–290. doi: 10.1038/337288a0. [DOI] [PubMed] [Google Scholar]
  • 43.Rowley A, et al. Failure to confirm the presence of a retrovirus in cultured lymphocytes from patients with Kawasaki syndrome. Pediatr. Res. 1991;29:417–419. doi: 10.1203/00006450-199105010-00001. [DOI] [PubMed] [Google Scholar]
  • 44.Leung DYM, et al. Toxic shock syndrome toxin-secreting Staphylococcus aureus in Kawasaki syndrome. Lancet. 1993;342:1385–1388. doi: 10.1016/0140-6736(93)92752-F. [DOI] [PubMed] [Google Scholar]
  • 45.Terai M, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J. Infect. Dis. 1995;172:558–561. doi: 10.1093/infdis/172.2.558. [DOI] [PubMed] [Google Scholar]
  • 46.Leung DYM, et al. Prevalence of superantigen-secreting bacteria in patients with Kawasaki disease. J. Pediatr. 2002;140:742–746. doi: 10.1067/mpd.2002.123664. [DOI] [PubMed] [Google Scholar]
  • 47.Esper F, et al. Association between a novel human coronavirus and Kawasaki disease. J. Infect. Dis. 2005;191:499–502. doi: 10.1086/428291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Shimizu C, et al. Human coronavirus NL63 is not detected in the respiratory tracts of children with acute Kawasaki disease. J. Infect. Dis. 2005;192:1767–1771. doi: 10.1086/497170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Dominguez SR, Anderson MS, Glode MP, Robinson CC, Holmes KV. Blinded case-control study of the relationship between human coronavirus NL63 and Kawasaki disease. J. Infect. Dis. 2006;194:1697–1701. doi: 10.1086/509509. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Catalano-Pons C, et al. Detection of human bocavirus in children with Kawasaki disease. Clin. Microbiol. Infect. 2007;13:1220–1222. doi: 10.1111/j.1469-0691.2007.01827.x. [DOI] [PubMed] [Google Scholar]
  • 51.Whitby, D. et al. Isolation of measles virus from a child with Kawasaki disease. Lancet338,1215 (1991). [DOI] [PubMed]
  • 52.Embil, J. A., McFarlane, E. S., Murphy, D. M., Krause, V. W. & Stuart, H. B. Adenovirus type 2 isolated from a patient with fatal Kawasaki disease. Can. Med. Assoc. J.132,1400 (1985). [PMC free article] [PubMed]
  • 53.Maury CPJ, Salo E, Pelkonen P. Elevated circulating tumor necrosis factor alpha in patients with Kawasaki disease. J. Lab. Clin. Med. 1989;113:651–654. [PubMed] [Google Scholar]
  • 54.Hirao J, Hibi S, Andoh T, Ichimura T. High levels of circulating interleukin-4 and interleukin-10 in Kawasaki disease. Int. Arch. Allergy Immunol. 1997;112:152–156. doi: 10.1159/000237447. [DOI] [PubMed] [Google Scholar]
  • 55.Lin CY, Lin CC, Hwang B, Chiang B. Serial changes of serum interleukin-6, interleukin-8, and tumor necrosis factor alpha among patients with Kawasaki disease. J. Pediatr. 1992;121:924–926. doi: 10.1016/S0022-3476(05)80343-9. [DOI] [PubMed] [Google Scholar]
  • 56.Ueno Y, et al. The acute phase nature of interleukin 6: studies in Kawasaki disease and other febrile illnesses. Clin. Exp. Immunol. 1989;76:337–342. [PMC free article] [PubMed] [Google Scholar]
  • 57.Nomura Y, Masuda K, Maeno N, Yoshinaga M, Kawano Y. Serum levels of interleukin-18 are elevated in the subacute phase of Kawasaki syndrome. Int. Arch. Allergy Immunol. 2004;135:161–165. doi: 10.1159/000080660. [DOI] [PubMed] [Google Scholar]
  • 58.Abe J, et al. Selective expansion of T cells expressing T-cell receptor variable regions Vβ2 and Vβ8 in Kawasaki disease. Proc. Natl Acad. Sci. USA. 1992;89:4066–4070. doi: 10.1073/pnas.89.9.4066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Abe J, et al. Characterization of T cell repertoire changes in acute Kawasaki disease. J. Exp. Med. 1993;177:791–796. doi: 10.1084/jem.177.3.791. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 60.Curtis N, Zheng R, Lamb JR, Levin M. Evidence for a superantigen mediated process in Kawasaki disease. Arch. Dis. Child. 1995;72:308–311. doi: 10.1136/adc.72.4.308. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 61.Yoshioka T, et al. Polyclonal expansion of TCRBV2- and TCRBV6-bearing T cells in patients with Kawasaki disease. Immunology. 1999;96:465–472. doi: 10.1046/j.1365-2567.1999.00695.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 62.Brogan PA, Shah V, Clarke LA, Dillon MJ, Klein N. T cell activation profiles in Kawasaki syndrome. Clin. Exp. Immunol. 2008;151:267–274. doi: 10.1111/j.1365-2249.2007.03567.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 63.Pietra BA, DeInocencio J, Giannini EH, Hirsch R. TCR V beta family repertoire and T-cell activation markers in Kawasaki disease. J. Immunol. 1994;153:1881–1888. [PubMed] [Google Scholar]
  • 64.Sakaguchi M, Kato H, Nishiyori A, Sagawa K, Itoh K. Characterization of CD4+ T helper cells in patients with Kawasaki disease (KD): preferential production of tumor necrosis factor-α (TNF-α) by V β2− or V β8− helper cells. Clin. Exp. Immunol. 1995;99:276–282. doi: 10.1111/j.1365-2249.1995.tb05545.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 65.Mancia L, et al. Characterization of the T-cell receptor V-β repertoire in Kawasaki disease. Scand. J. Immunol. 1998;48:443–449. doi: 10.1046/j.1365-3083.1998.00415.x. [DOI] [PubMed] [Google Scholar]
  • 66.Sourdive DJD, et al. Conserved T cell receptor repertoire in primary and memory CD8 T cell responses to an acute viral infection. J. Exp. Med. 1998;188:71–82. doi: 10.1084/jem.188.1.71. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 67.Deckhut AM, et al. Prominent usage of V beta 8.3 T cells in the H-2Db-restricted response to an influenza A virus nucleoprotein epitope. J. Immunol. 1993;151:2658–2666. [PubMed] [Google Scholar]
  • 68.Chen D, Lee F, Cebra JJ, Rubin DH. Predominant T-cell receptor Vβ usage of intraepithelial lymphocytes during the immune response to enteric reovirus infection. J. Virol. 1997;71:3431–3436. doi: 10.1128/jvi.71.5.3431-3436.1997. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 69.Cose SC, Kelly JM, Carbone FR. Characterization of diverse primary herpes simplex virus type 1 gB-specific cytotoxic T-cell response showing a preferential V beta bias. J. Virol. 1995;69:5849–5852. doi: 10.1128/jvi.69.9.5849-5852.1995. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 70.Kashii Y, et al. Analysis of T-cell receptor V beta repertoire in liver-infiltrating lymphocytes in chronic hepatitis C. J. Hepatol. 1997;26:462–470. doi: 10.1016/S0168-8278(97)80408-4. [DOI] [PubMed] [Google Scholar]
  • 71.Choi IH, et al. Clonal expansion of CD8+ T cells in Kawasaki disease. J. Immunol. 1997;159:481–486. [PubMed] [Google Scholar]
  • 72.Matsubara K, et al. Development of serum IgM antibodies against superantigens of Staphylococcus aureus and Streptococcus pyogenes in Kawasaki disease. Clin. Exp. Immunol. 2006;143:427–434. doi: 10.1111/j.1365-2249.2006.03015.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Nomura Y, Yoshinaga M, Masuda K, Takei S, Miyata K. Maternal antibody against toxic shock syndrome toxin-1 may protect infants younger than 6 months of age from developing Kawasaki syndrome. J. Infect. Dis. 2002;185:1677–1680. doi: 10.1086/340513. [DOI] [PubMed] [Google Scholar]
  • 74.Gupta-Malhotra M, Viteri-Jackson A, Thomas W, Zabriskie JB. Antibodies to highly conserved peptide sequence of staphylococcal and streptococcal superantigens in Kawasaki disease. Exp. Mol. Pathol. 2004;76:117–121. doi: 10.1016/j.yexmp.2003.12.003. [DOI] [PubMed] [Google Scholar]
  • 75.Terai M, et al. The absence of evidence of staphylococcal toxin involvement in the pathogenesis of Kawasaki disease. J. Infect. Dis. 1995;172:558–561. doi: 10.1093/infdis/172.2.558. [DOI] [PubMed] [Google Scholar]
  • 76.Grunebaum E, et al. The role of anti-endothelial cell antibodies in Kawasaki disease — in vitro and in vivo studies. Clin. Exp. Immunol. 2002;130:233–240. doi: 10.1046/j.1365-2249.2002.02000.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 77.Amano S, et al. General pathology of Kawasaki disease. Acta Pathol. Jpn. 1980;30:681–694. [PubMed] [Google Scholar]
  • 78.Yutani C, et al. Histopathological study on right endomyocardial biopsy of Kawasaki disease. Br. Heart J. 1980;43:589–592. doi: 10.1136/hrt.43.5.589. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 79.Yasukawa K, et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation. 2002;105:766–769. doi: 10.1161/hc0602.103396. [DOI] [PubMed] [Google Scholar]
  • 80.Brown TJ, et al. CD8 T lymphocytes and macrophages infiltrate coronary artery aneurysms in acute Kawasaki disease. J. Infect. Dis. 2001;184:940–943. doi: 10.1086/323155. [DOI] [PubMed] [Google Scholar]
  • 81.Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler. Thromb. Vasc. Biol. 2003;23:576–581. doi: 10.1161/01.ATV.0000065385.47152.FD. [DOI] [PubMed] [Google Scholar]
  • 82.Miura M, Garcia FL, Crawford SE, Rowley AH. Cell adhesion molecule expression in coronary artery aneurysms in acute Kawasaki disease. Pediatr. Infect. Dis. J. 2004;23:931–936. doi: 10.1097/01.inf.0000142171.91235.fc. [DOI] [PubMed] [Google Scholar]
  • 83.Suzuki A, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease. Circulation. 2000;101:2935–2941. doi: 10.1161/01.CIR.101.25.2935. [DOI] [PubMed] [Google Scholar]
  • 84.Freeman AF, et al. Angiogenesis in fatal acute Kawasaki disease coronary artery and myocardium. Pediatr. Cardiol. 2005;26:578–584. doi: 10.1007/s00246-005-0801-2. [DOI] [PubMed] [Google Scholar]
  • 85.Shingadia D, O'Gorman M, Rowley AH, Shulman ST. Surface and cytoplasmic immunoglobulin expression on circulating B-lymphocytes in acute Kawasaki disease. Pediatr. Res. 2001;50:538–543. doi: 10.1203/00006450-200110000-00019. [DOI] [PubMed] [Google Scholar]
  • 86.Murphy FA, Gibbs EPJ, Horzinek MC, Studdert MJ. Veterinary Virology: the Third Edition. 1999. pp. 277–292. [Google Scholar]
  • 87.Rowley AH, et al. RNA-containing cytoplasmic inclusion bodies in ciliated bronchial epithelium months to years after acute Kawasaki disease. PLoS ONE. 2008;3:e1582. doi: 10.1371/journal.pone.0001582. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 88.Maiztegui JI, Fernandez NJ, deDamilano AJ. Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome. Lancet. 1979;2:1216–1217. doi: 10.1016/S0140-6736(79)92335-3. [DOI] [PubMed] [Google Scholar]
  • 89.Enria DA, Briggiler AM, Fernancez NJ, Levis SC, Maiztegui JI. Importance of dose of neutralizing antibodies in treatment of Argentine haemorrhagic fever with immune plasma. Lancet. 1984;2:255–256. doi: 10.1016/S0140-6736(84)90299-X. [DOI] [PubMed] [Google Scholar]
  • 90.Kenyon RH, Condie RM, Jahrling PB, Peters CJ. Protection of guinea pigs against experimental Argentine hemorrhagic fever by purified human IgG: importance of elimination of infected cells. Microb. Pathog. 1990;9:219–226. doi: 10.1016/0882-4010(90)90010-N. [DOI] [PubMed] [Google Scholar]
  • 91.Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: I. Pathology and morphogenesis of the vascular changes. Jpn. Circ. J. 1979;43:633–643. doi: 10.1253/jcj.43.633. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 92.Naoe S, et al. Pathological observations concerning the cardiovascular lesions in Kawasaki disease. Cardiol. Young. 1991;1:212–220. doi: 10.1017/S1047951100000408. [DOI] [Google Scholar]
  • 93.Amano S, Hazama F, Hamashima Y. Pathology of Kawasaki disease: II. Distribution and incidence of the vascular lesions. Jpn. Circ. J. 1979;43:741–748. doi: 10.1253/jcj.43.741. [DOI] [PubMed] [Google Scholar]
  • 94.Freeman AF, et al. Inflammatory pulmonary nodules in Kawasaki disease. Pediatr. Pulmonol. 2003;36:102–106. doi: 10.1002/ppul.10333. [DOI] [PubMed] [Google Scholar]
  • 95.Terai M, et al. Peripheral blood eosinophilia and eosinophil accumulation in coronary microvessels in acute Kawasaki disease. Pediatr. Infect. Dis. J. 2002;21:777–780. doi: 10.1097/00006454-200208000-00015. [DOI] [PubMed] [Google Scholar]
  • 96.Yilmaz A, et al. Activated myeloid dendritic cells accumulate and co-localize with CD3+ T cells in coronary artery lesions in patients with Kawasaki disease. Exp. Mol. Pathol. 2007;83:93–103. doi: 10.1016/j.yexmp.2007.01.007. [DOI] [PubMed] [Google Scholar]
  • 97.Terai M, et al. Imbalance among T-cell subsets in patients with coronary arterial aneurysms in Kawasaki disease. Am. J. Cardiol. 1987;60:555–559. doi: 10.1016/0002-9149(87)90304-3. [DOI] [PubMed] [Google Scholar]
  • 98.Orlowski JP, Mercer RD. Urine mercury levels in Kawasaki disease. Pediatrics. 1980;66:633–636. [PubMed] [Google Scholar]
  • 99.Ohtaki C, Tomiyama T, Suzuki M, Hayakawa H, Kaga M. Leptospiral antibody and MLNS. J. Pediatr. 1978;93:896. doi: 10.1016/S0022-3476(78)81125-1. [DOI] [PubMed] [Google Scholar]
  • 100.Shinomiya N, et al. Variant Streptococcus sanguis as an etiologic agent of Kawasaki disease. Prog. Clin. Biol. Res. 1987;250:571–572. [PubMed] [Google Scholar]
  • 101.Catalano-Pons C, et al. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants. Clin. Infect. Dis. 2005;41:e53–e56. doi: 10.1086/432578. [DOI] [PubMed] [Google Scholar]
  • 102.Lee SJ, Lee KY, Han JW, Lee JS, Whang KT. Epstein Barr virus antibodies in Kawasaki disease. Yonsei Med. J. 2006;47:475–479. doi: 10.3349/ymj.2006.47.4.475. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Nature Reviews. Microbiology are provided here courtesy of Nature Publishing Group

RESOURCES